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Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying
virally infected or cancerous cells through targeted cytotoxicity and further assisting in the
immune response by releasing inflammatory cytokines. NK cells are thought to contribute
to the process of tumor killing by certain therapeutic monoclonal antibodies (mAb) by direct-
ing antibody-dependent cellular cytotoxicity (ADCC) through FcγRIIIA (CD16). Numerous
therapeutic mAb have been developed that target distinct cancer-specific cell markers and
may direct NK cell-mediated ADCC. Recent therapeutic approaches have combined some
of these cancer-specific mAb with additional strategies to optimize NK cell cytotoxicity.
These include agonistic mAb targeting NK cell activating receptors and mAbs blocking NK
cell inhibitory receptors to enhance NK cell functions. Furthermore, several drugs that can
potentiate NK cell cytotoxicity through other mechanisms are being used in combination
with therapeutic mAb. In this review, we examine the mechanisms employed by several
promising agents used in combination therapies that enhance natural or Ab-dependent
cytotoxicity of cancer cells by NK cells, with a focus on treatments for leukemia and multiple
myeloma.
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INTRODUCTION
Natural killer (NK) cells are generally known for the ability to
mediate spontaneous“natural”cytotoxicity of major histocompat-
ibility complex class I (MHC-I)-deficient tumor or virus-infected
cells. NK cells kill target cells through the release of perforin and
granzymes from cytolytic granules or the surface expression of Fas
ligand or TNF-related apoptosis-inducing ligand (TRAIL). Acti-
vated NK cells are also a potent source of interferon (IFN)-γ,
tumor necrosis factor (TNF)-α, and a variety of other cytokines
and chemokines that contribute significantly to early immune
responses.
The activation of NK cells is controlled by a balance of sig-
nals emanating from a collection of germline-encoded activating
and inhibitory receptors. Several inhibitory receptors, including
CD94/NKG2A, members of the highly polymorphic killer cell-
Ig-like receptor (KIR) family and ILT2/LIR-1/CD85j, play critical
roles in tolerizing NK cells toward healthy cells by binding to
MHC-I ligands [human leukocyte antigen (HLA)-A, -B, and -C
allotypes] expressed on virtually all healthy cells (1). When NK
cells engage with MHC-I-expressing healthy cells, the inhibitory
receptors transduce negative signaling that efficiently abrogate
stimulatory signals from co-engaged activating receptors at the
immunological synapse (2–4). Many tumors and virus-infected
cells down-regulate their surface expression of MHC-I to avoid
recognition by the antigen receptor on cytotoxic T cells, but these
abnormal cells inherently become susceptible to NK cell-mediated
attack in the absence of the tolerizing MHC-I ligands.
Activating receptors expressed on human NK cells include
FcγRIIIA (CD16), activating forms of KIR, 2B4, NKG2D, and
the natural cytotoxicity receptors (NCR), which are also known
as NKp30, NKp44, and NKp46 (5, 6). Of these, the NCR and
NKG2D are particularly important receptors for triggering NK cell
responses toward tumor target cells (7). In contrast to inhibitory
receptors, triggering of the activating receptor NKG2D is a key
mechanism by which NK cells recognize stressed or diseased cells
and destroy them (8). NKG2D specifically recognizes MHC chain-
related (MIC) A, MICB, and UL16-binding proteins (ULBPs) in
humans, which are HLA-related molecules lacking peptide pre-
sentation capacity that are not expressed on normal cells but are
up-regulated on stressed cells, such as tumors (8, 9).
Thus, NK cells are important effectors in immune responses to
tumors and viral infections, and increased understanding of the
mechanisms controlling NK cell activation has led to the develop-
ment of therapeutic agents that can improve their responsiveness.
While these agents show promise, results are inconsistent between
patients due to inherent differences in activity/function of an indi-
vidual’s immune system, and expression of distinct biomarkers on
cancers that can differentially influence NK cell responsiveness.
A growing variety of treatment options can improve outcome
for individual patients. Novel treatment regimens combining new
and old therapies are even showing promise among relapsed and
refractory patients. Here, we review some of the currently avail-
able therapies that are known to stimulate NK cell functions and
how they are being used in combination with other agents to boost
anti-tumor responses in cancer patients.
ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
FcγRIIIA (CD16) provides NK cells with the capacity to mediate
antibody-dependent cellular cytotoxicity (ADCC) upon recog-
nition of the Fc segment of IgG bound to cell surfaces. This
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antigen-specific NK cell targeting mechanism appears to play an
important role in tumor eradication by several therapeutic tumor-
specific mAb, such as herceptin, rituximab, and elotuzumab. Inter-
estingly, Deguine et al. recently suggested that NKG2D engage-
ment might be crucial for NK cell-mediated ADCC responses.
In that study, mouse tumors expressing NKG2D ligands induced
enhanced ADCC degranulation, while responses were reduced
toward tumors lacking NKG2D ligand. The results indicate that
the mAb-FcR interaction mainly stabilized adhesion with the
target cell to contribute contact stability, while NKG2D trigger-
ing provided the activation threshold needed to trigger NK cell
degranulation (10). This concept is supported by earlier work
in a mouse model of renal cancer that showed NKG2D liga-
tion does not stimulate strong adhesion with tumor cells. In that
report, target cells that did not express ICAM-1 were not killed in
an NKG2D-dependent manner, but transfection of ICAM-1 into
these cells restored NKG2D-mediated cytotoxicity (11).
An emerging strategy to enhance NK cell-mediated ADCC
responsiveness is to inhibit the shedding of CD16 that occurs
after NK cell activation (12, 13). Specifically, CD16 can be cleaved
by metalloproteinases after being triggered by an IgG-opsinized
target cell or treatment with IL-2, but if metalloproteinases are
inhibited, CD16 is not shed. In fact, CD16 signaling is sustained
and target cell killing and cytokine production are enhanced in
the presence of metalloproteinase inhibitors (14). Furthermore,
combining metalloproteinase inhibition with a bispecific antibody
(against CD16 and CD33) resulted in a sustained and very specific
anti-tumor response (15). Such a combination strategy has the
potential to substantially increase NK cell responses to cancer.
An additional immunoglobulin-based strategy to target more
immune responses toward tumor cells is to create bispecific or
trispecific antibodies. The engineering of bispecific monoclonal
antibodies (mAb) that create surrogate bridging between acti-
vating receptors on T or NK cells with tumor-specific antigens
have shown therapeutic promise for decades (16). A common
bispecific design theme to target NK cells has employed fusing
antibody Fv domains that bind CD16 with Fv domains that bind
tumor cell markers, such as CD30 (17), ErbB2 (18–20) or CD19
(21, 22). These constructs can trigger ADCC responses by NK
cells and monocytes/macrophages through the CD16 FcR with-
out the need for an incorporated Fc domain. As a cautionary
tale for appropriate design, a bispecific incorporating a CD16-
binding Fv domain in combination with a CD16-binding Fc
domain was found in an early phase I study to induce toxicity
through dimeric engagement of the FcR on the surface of mono-
cytes and NK cells in the blood, which induced rapid release of
cytokines, including TNF-α, IL-6, and IL-8 (18). Modern recom-
binant approaches fuse Fv domains into single chain constructs
that have been termed bispecific or trispecific killer cell engagers
(BiKEs or TriKEs), which lack Fc domains entirely. Importantly,
these BiKEs and TriKEs can be highly effective at inducing NK
cell ADCC and cytokine responses (22). In another approach,
von Strandmann et al. created a bispecific protein (ULBP-BB4)
that fused the NKG2D ligand, ULBP2, onto a single chain Fv
targeting CD138, which is highly expressed on a number of
malignancies, including multiple myeloma (MM). In xenograft
mouse models injected with human tumor cells and human
PBLs, ULBP-BB4 demonstrated potent anti-tumor activity while
not significantly harming healthy cells (23). Many researchers
have also developed trivalent antibodies composed of two tumor
antigen-recognition domains and one monovalent domain that
recognizes NK cells (19–21, 24). If properly manipulated for
safety, bispecific and trispecific antibodies offer a very targeted
approach to effective tumor therapy that can directly involve NK
cell effector function.
THE USE OF NK CELL-RELATED IMMUNE THERAPIES TO
TREAT MULTIPLE MYELOMA
A common proving ground for testing immune therapies that
stimulate NK cell activity has been MM. MM is a deadly hema-
tologic cancer characterized by clonal expansion of malignant
plasma cells that reside in the bone marrow and thrive on inter-
actions with the bone marrow microenvironment (25). Despite
advances in treatment strategies, MM remains an incurable dis-
ease, with about 20,000 newly diagnosed cases and over 10,000
deaths per year in the U.S. (26). Novel therapies have improved
survival over the last decade, including autologous hematopoi-
etic stem cell transplantation (HSCT) and the use of new drugs
(27). Allogeneic stem cell transplantation can be curative, but
is often associated with high transplantation-related mortality
(28). Despite these advanced therapeutic options, median sur-
vival remains around 4–5 years in adults (29) and the development
of better treatments is essential. Interestingly, evidence is accu-
mulating that NK cells may play a prominent role in immune
responses toward MM and can also contribute to graft-versus-
myeloma responses in haploidentical HSCT (30), It is becoming
clear that NK cells can elicit potent allogeneic and autologous
responses to myeloma cells in vitro and in patients (30, 31). Given
the importance of NK cells in immune responses toward MM,
combination therapies that enhance NK cell functions are show-
ing promise in treating this deadly disease, as will become evident
in the following discussion.
IMMUNOMODULATORY DRUGS (IMiDs®)
Thalidomide, lenalidomide, and pomalidomide form a new class
of immunomodulatory drugs, referred to as IMiDs, which can
broadly stimulate the functions of NK cells and T cells to treat
cancer (32). Thalidomide is a glutamic acid derivative with a
dark history as a therapeutic agent, since it caused severe birth
defects when used to treat morning sickness in pregnant women
in the late 1950s. Nonetheless, it was subsequently found to
have anti-inflammatory, anti-angiogenic, anti-proliferative, and
immunomodulatory properties that fostered further investigation
(33–35). The anti-inflammatory properties of thalidomide are at
least partially due to potent inhibition of the production of TNF-
α by activated monocytes (35). Lenalidomide and pomalidomide
are more potent thalidomide analogs that have since emerged
(36), and pomalidomide is even more potent at co-stimulating
T cells than lenalidomide (37). Since these IMiDs can enhance the
functions of T cells and NK cells, suppress angiogenesis, inhibit
TNF-α production, and directly repress tumor cell growth, they
are potentially beneficial in treating cancer. To date, both lenalido-
mide and pomalidomide have been used to treat MM and a variety
of other cancers.
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The mechanism of immune stimulation by IMiDs is com-
plex and not entirely established (32). Treatment of patients with
lenalidomide has been shown to increase the overall frequency of
NK cells in peripheral blood, suggesting that they either proliferate
or migrate into the bloodstream (38–40). Lenalidomide does not
appear to stimulate NK cells directly, however, but instead func-
tions through effects on other leukocytes in peripheral blood (40).
Stimulation of T cells by lenalidomide overcomes the need for
signals from antigen presenting cells and induces increased prolif-
eration and enhanced production of the type 1 cytokines, IL-2, and
IFN-γ (37, 41, 42). At least part of the stimulatory effects of IMiDs
on NK cells appears to be due to the T cell production of IL-2,
which is a potent growth factor for NK cells (43, 44). Both lenalido-
mide and pomalidomide have also been shown to increase ADCC
activity by NK cells (44, 45). At least part of this effect may result
from an increased frequency of the CD56dim NK cells expressing
CD16 and LFA-1 in peripheral blood, which are responsible for
mediating ADCC (46). This ability of IMiDs to augment ADCC
has been borne out in clinical studies, particularly in combination
with the CD20-targeting antibody rituximab, where significant
activity has been seen in relapsed/refractory B-cell lymphomas
and chronic lymphocytic leukemia (47, 48). In MM, lenalidomide
is usually used in combination with steroids (49, 50). However,
the enhanced NK cell-mediated responses by lenalidomide can be
reversed in combination with dexamethasone (40), suggesting that
using steroids long-term in combination with lenalidomide may
be counterproductive to its immune-stimulatory effects, and that
steroid-free combinations should be explored. It should also be
noted that tumor cell lines cultured in lenalidomide become more
susceptible to NK cell-mediated lysis, due to their increased expres-
sion of ligands for NK cell activating receptors (38–40, 51). Taken
together, NK cell-mediated anti-tumor responses can be stimu-
lated in a variety of ways by IMiDs, and this enhanced function
can be beneficial in treating cancer.
BORTEZOMIB
Bortezomib is an inhibitor of the 26S proteasome that is currently
used to treat MM and lymphoma. Inhibition of the proteasome has
several direct negative impacts on tumor cells, including inhibit-
ing proliferation and inducing apoptosis, but bortezomib-treated
tumor cells also become more susceptible to attack by NK cells
(52). Upon inhibition of the proteasome, tumor cells are inca-
pable of processing and presenting proteolytic peptide fragments
on MHC-I molecules on the plasma membrane. Consequently,
bortezomib down-regulates the surface expression of MHC-I on
tumor cells in vitro and in vivo (53), thereby reducing the levels of
this important protein for NK cell tolerance and enhancing sus-
ceptibility to NK cell-mediated natural and antibody-dependent
cytotoxicity (54, 55). Bortezomib treatment can augment the effi-
cacy of adoptively transferred NK cells in murine tumor models
(56), and this approach has now been translated to the clinic for
cancer patients (57).
ELOTUZUMAB
A promising new monoclonal antibody candidate for treatment
of MM is elotuzumab (formerly HuLuc63). Elotuzumab is a fully
humanized antibody that recognizes the SLAM family member
CS1 (CRACC, SLAMF7, CD319), a surface glycoprotein normally
expressed on NK cells, monocytes, mature dendritic cells, a subset
of T cells, and stimulated B cells (58, 59). Normal plasma cells
express high levels of CS1, which correlates with high expres-
sion on MM cells (60). CS1 is an attractive therapeutic ADCC
target because the available clinical data indicate that expression
persists on MM cells even after conventional treatments (61–63).
CS1 was originally found to engage in homotypic interactions
as a self-ligand, and pretreatment of a NK cell line with recom-
binant CS1-Ig fusion protein was shown to stimulate killing of
K562 target cells, apparently by directly activating the NK cells via
homotypic interaction (64). Two separate reports found high CS1
expression in most MM cases studied, and elotuzumab was found
to significantly increase NK cell-mediated ADCC of primary MM
cells (65, 66).
While initiation of NK cell-mediated ADCC upon engagement
with CD16 is the best characterized function of elotuzumab, the
exact mechanism(s) of action is unclear (67). Importantly, CS1 is
also considered a co-stimulatory receptor on NK cells (64, 68), and
recent evidence indicates that elotuzumab may also stimulate NK
cells directly through direct interactions with CS1 on the NK cell
surface (69). As an additional potential mechanism, elotuzumab
may interfere with interactions of MM cells with the bone marrow
microenvironment, which is a key requirement for tumor sur-
vival and proliferation (60, 67). MM cell interactions with bone
marrow stromal cells, osteoclasts, and osteoblasts lead to bone
deterioration, angiogenesis, and MM cell survival and prolifera-
tion (70), so disrupting the ability of MM cells to interact with the
microenvironment could provide multiple benefits. All of these
potential mechanisms of action continue to be explored, though
so far the data continue to indicate that NK cells contribute to the
therapeutic efficacy of this anti-CS1 monoclonal antibody.
Clinically, elotuzumab used alone was well-tolerated and led to
disease stabilization in a subset of relapsed/refractory myeloma
patients (63). More promising clinical activity was seen, how-
ever, when it was used in combination with lenalidomide and
dexamethasone, with over 80% of relapsed patients responding
in phase I and II trials, and progression-free survival signifi-
cantly longer (median 26.9 months at the 10 mg/kg dose) than that
previously observed for lenalidomide/dexamethasone alone (62).
Elotuzumab-mediated ADCC of MM targets by NK cells can be
enhanced in vitro by pretreatment with a proteasome inhibitor (54,
66), and a small combination study of elotuzumab and bortezomib
in relapsed/refractory myeloma patients showed this combination
to be safe, with preliminary efficacy observed (61). Currently, three
randomized phase III trials are underway adding elotuzumab to
either bortezomib or lenalidomide/dexamethasone, in both newly
diagnosed and relapsed/refractory MM patients. These studies will
more definitively assess if there is a benefit to adding elotuzumab
to these standard therapies.
KIR-BLOCKING MONOCLONAL ANTIBODY
Allogeneic HSCT has emerged as an effective treatment option for
a variety of hematological cancers after chemotherapeutic ablation
of the recipient’s immune cells (71). Because of the high polymor-
phic variability of KIR and MHC-I in the human population,
variability of these receptor/ligand pairs should be considered in
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the context of transplantation. Velardi and colleagues first reported
that donor allogenicity of NK cells in HSCT to treat acute myeloid
leukemia (AML) resulted in a double benefit by enhancing anti-
leukemia responses, while reducing graft-versus-host disease (72).
In the absence of an HLA-identical sibling donor, haploidentical
HSCT is commonly used, in which a mismatch exists in at least
one HLA allele. This mismatch improves the odds that at least one
inhibitory KIR in the donor NK cells lacks an MHC-I ligand in the
transplant recipient. In this scenario, the donor-derived NK cells
are less inhibited and considered to be more capable of triggering
a graft-versus-leukemia effect. KIR/HLA mismatch in HSCT has
resulted in improved outcomes by several groups, specifically in
treating AML (73–75), and may play a role in myeloma as well
(30, 76). It is believed that NK cell-mediated autoimmunity does
not occur in these patients because healthy cells are less likely to
up-regulate the stress ligands that trigger NK cells (77). It is impor-
tant to note that recent evidence indicates that donors expressing
activating KIR (especially donors expressing KIR2DS1, but lack-
ing its ligand, HLA-C2) also contribute significantly to improved
outcomes in HSCT to treat AML (78, 79). These results indicate
that certain engineered mismatches of KIR/HLA interactions in
the context of HSCT can significantly influence NK cell responses
in AML patients and perhaps other cancers.
In addition to exploiting KIR/HLA ligand mismatch in the
context of HSCT, monoclonal antibody-mediated blockade of
the KIR/HLA interaction has emerged as a potential cancer
immunotherapy to lower the threshold of NK cell activation.
The in vitro use of mAb to block KIR function was first found
to increase cytokine production in T cells in 1996 (2). To fur-
ther test this concept in vitro, Binyamin et al. potentiated NK cell
responses to autologous EBV-transformed B cells by combining
a panel of mAbs to block numerous NK cell inhibitory recep-
tors (KIR, CD94/NKG2A, and ILT2/LIR-1/CD85j) in combination
with the B cell-specific anti-CD20 mAb rituximab to simultane-
ously reduce inhibitory signals and trigger ADCC, respectively
(80). Importantly, NK cell-mediated cytotoxicity of the trans-
formed target cells was not elevated by inhibitory receptor block-
ade alone, suggesting that other tolerizing mechanisms effectively
prevent the attack of normal cells in the context of these inhibitory
receptor-blocking conditions.
Based on this concept, a humanized KIR-blocking mAb
IPH2101 (formerly 1-7F9) has been developed and is currently
being tested in clinical trials. IPH2101 is a pan-specific anti-KIR
antibody that binds KIR2DL1, -2 and -3, which are the most
relevant inhibitory KIR family members, due to their combined
capacity to recognize all allotypes of HLA-C. The antibody was
shown to block the interaction between these inhibitory KIR2DL
and HLA-C and also binds the activating receptors KIR2DS1 and
KIR2DS2, although the functional impacts of these interactions
have not been formally tested (77). In vitro preclinical studies
demonstrated that IPH2101 mAb augments NK cell cytotoxicity
of HLA-C-expressing tumor cells without targeting normal blood
mononuclear cells, which is critical to assure that NK cells remain
tolerant in treated patients (77). This was confirmed in a preclinical
mouse model that was engineered to co-express KIR2DL3 and its
ligand, HLA-Cw3, which was able to license or educate the mouse
NK cells. When KIR was then blocked in vivo with IPH2101, the
mouse NK cells were able to destroy HLA-Cw3-positive target cells
without development of autoimmunity (81).
In view of the capacity of NK cells to respond to myeloma cells,
phase I clinical trials have been initiated to treat MM patients with
IPH2101 and the modified variant, IPH2102. When used alone
in patients, the side effects of IPH2101 were minimal with no
evidence of autoimmunity, and ex vivo functional assays showed
enhanced NK cell cytotoxicity (82, 83). A trial of IPH2101 in com-
bination with lenalidomide has since been initiated, based upon a
variety of effects by these reagents that can potentially synergize
to enhance NK cell responses. IPH2101 is expected to enhance
NK cell killing by blocking inhibitory signals, while lenalidomide
can stimulate general NK cell function and may even up-regulate
triggering ligands on MM cells (51).
Importantly, the addition of KIR blocking mAbs may prove to
be an asset in treating a variety of cancers, as a way to boost the
potential of NK cells to kill stressed or cancerous cells, while retain-
ing general NK cell tolerance toward normal cells. Nonetheless, it
is possible that optimal clinical responses may require a combi-
nation therapy of multiple antibodies blocking a wider variety of
inhibitory receptors expressed on NK cells, such as KIR3DL fam-
ily members, CD94/NKG2A, and ILT2/LIR-1/CD85j, as well as the
addition of an ADCC targeting mAb to stimulate tumor-specific
cytotoxicity, as demonstrated by the in vitro studies of Binyamin
et al. described earlier (80).
AGENTS PROMOTING THE EXPRESSION OF NKG2D LIGANDS
ON TUMOR CELLS
The human NKG2D ligands MICA, MICB, and ULBPs are com-
monly up-regulated on stressed or infected cells and thereby
provide a key recognition element for NK cell-mediated attack
of many cancer cells (8, 9). Several cancer types are able to
shed NKG2D ligands into the sera as an immune evasive mecha-
nism, and these soluble ligands have been shown to cause down-
regulation of NKG2D on NK cells, which leads to a stunted
immune response (84–87). Demonstrating the high frequency
of shed ligands, Hilpert et al. recently found at least one solu-
ble NKG2D ligand in the sera of 183 leukemia patients analyzed,
and culture of NK cells in leukemia patient sera resulted in down-
regulation of NKG2D expression (88). Shedding of the NKG2D lig-
and, MICA, by chronic lymphocytic leukemia cells can be induced
upon translocation of the endoplasmic reticulum-resident pro-
teins ERp5 and GRP78 to the tumor cell surface (89). Additionally,
shedding of MICA/B has been attributed to proteolytic activity of
the ADAM10 and ADAM17 metalloproteinases in some tumor
cell lines (90). The MICA*008 allele can also be released into exo-
somes, which can subsequently down-regulate NKG2D expression
and reduce NK cell-mediated cytotoxicity (90, 91). On the other
hand, the expression of CEACAM1 in cancer cells can cause the
intracellular retention of NKG2D ligands, thereby limiting NK cell
detection through NKG2D (92). These observations have made
the retention/upregulation of NKG2D ligands on tumor cells an
attractive goal for cancer therapy.
Many drugs that were first considered for cancer therapy
because they can alter gene expression in tumor cells were subse-
quently found to also increase the susceptibility of tumor cells to
cytotoxicity by NKG2D-expressing NK cells. These drugs include
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those that promote gene upregulation (93–96), differentiation
(97–99), and DNA or protein damage (100–103). For exam-
ple, HDAC inhibitors cause the upregulation of NKG2D ligands,
MICA/B and ULBPs, in tumor cells but not healthy cells. Treatment
with the HDAC inhibitor valproic acid (VPA, valproate) leads to
higher expression of NKG2D ligands at the transcriptional and
translational levels by inducing acetylation of the histones bound
to MICA and MICB gene promoters (104, 105). The relatively low
toxicity and low occurrence of off target effects of VPA make it
a reasonable means of boosting effector cell function. Further-
more, treating cultured cells with VPA and the DNA methylation
inhibitor hydralazine was shown to increase dimethylated MICA/B
gene promoters, thereby further stimulating transcription (106,
107). The addition of a metalloproteinase inhibitor has also been
shown to block the proteolytic cleavage of NKG2D ligands, as
a means to further decrease shedding into the sera when used
in conjunction with VPA treatment (108). Lastly, spironolactone,
a diuretic commonly used to treat heart failure and high blood
pressure, has very recently been found to also upregulate NKG2D
ligands and therefore increase NK cell cytotoxicity of colon cancer
cell lines (109).
Glycogen synthase kinase (GSK)-3 has recently been discovered
as a new target to promote MICA/B upregulation. GSK3 inhibitors
have been widely used to suppress the proliferation of malig-
nant lymphoid cells, but Fionda et al. recently showed that GSK3
inhibition also increased MICA expression at the protein and
mRNA levels in MM cells (110). In conjunction with the increased
MICA expression, the addition of the GSK3 inhibitor significantly
enhanced NK cell-mediated cytotoxicity of tumor cells. Mecha-
nistically, GSK3 inhibition correlated with the down-regulation of
STAT3, which is a negative regulator of MICA expression (110).
In addition, the combination of lenalidomide with GSK3 inhibi-
tion further enhanced MICA expression, which further supports
the combined mechanistic benefit of these agents with current
anti-tumor therapies.
ANTI-CD137 MONOCLONAL ANTIBODIES
CD137 (4-1BB, TNFRSF9) is an inducible member of the TNF
receptor superfamily that functions as a co-stimulatory signaling
molecule on the surface of activated T and NK cells. CD137 lig-
ation further augments activation of these cells, increasing their
proliferation, cytokine secretion, and effector function, and pre-
venting activation-induced cell death (111, 112). Treatment with
agonist anti-CD137 mAb can mimic this co-stimulatory signal,
leading to regression of large tumors in multiple murine models,
including B-cell lymphoma and myeloma (111, 113–115). This
effect requires CD8+ T cells, but is also dependent upon the pres-
ence of NK cells (116, 117), implying an impact on these cells
as well. Many diverse types of tumors express elevated levels of
the CD137 ligand, CD137L, accompanied by increased expression
of CD137 on immune cells within the tumor environment, while
expression of either is negligible on healthy cells (115, 118–120).
There are conflicting data regarding the effects of anti-CD137
mAb on NK cells. CD137 engagement on mouse NK cells con-
sistently results in activation, but this can be either activating or
inhibitory in humans, depending on the setting or model used.
In human leukemia cells, the CD137/CD137L interaction can
also result in bidirectional signaling to suppress NK cell-mediated
responses; CD137 recognition of CD137L on leukemic cells trans-
mits inhibitory signals into the NK cell to impair cytokine pro-
duction and cytotoxicity responses and CD137L engagement by
CD137 induces the production of TNF and immunosuppres-
sive interleukin (IL)-10 by the tumor cells (119). Inhibiting this
interaction using soluble CD137-Fc or a “blocking” anti-CD137
mAb can restore NK cell cytotoxicity (119). Taking this ratio-
nale one step further, Buechele et al. suggested the potential
merits of a dual strategy of blocking CD137/CD137L interac-
tion and neutralizing immunosuppressive TNF (121). Lin et al.
demonstrated that human NK cells up-regulate CD137 in vitro
following Fc-receptor engagement, which promotes release of
pro-inflammatory cytokines but decreased cytotoxicity against
K562 targets. This implies a negative impact of CD137 expres-
sion and signaling in human NK cells, though the direct impact
of CD137 ligation was not tested in this model (122, 123). In con-
trast, Kohrt et al. have shown that following FcR-induced CD137
up-regulation on NK cells, adding an agonist anti-CD137 mAb
known to induce CD137 signaling actually enhances NK cell-
mediated ADCC toward rituximab- or trastuzumab-coated target
cells (124, 125). Whether this antibody may also be working by
preventing CD137 on immune cells from binding to CD137L
and inducing “reverse” signaling within the tumor cell was not
explored in these studies. Nonetheless, these data have led to an
ongoing clinical trial (NCT01775631) combining rituximab with
agonist anti-CD137 mAb (BMS-663513, urelumab) in patients
with relapsed/refractory B-cell malignancies.
These inconsistent findings on the impacts of manipulating
CD137 in NK cells are likely the result of signaling differences
between mice and men, the use of different CD137-targeting
reagents, and even between different hematopoietic versus non-
hematopoietic cancer models (120). For clinical relevance, it will
be important to better understand the human mechanistic impact
of CD137/CD137L interaction in order to properly exploit the
potential treatment options. The role of CD137/CD137L inter-
actions on interplay between NK cells and CD4+, CD8+, and
regulatory T cells (Tregs) is also incompletely understood (126).
For instance, the depletion of immunosuppressive Tregs has been
shown to enhance the anti-tumor activity of anti-CD137 mAb
(115). However, CD137 engagement on CD4+ and CD8+ T cells is
believed to always be activating in mice and men (126). Nonethe-
less, while the exact mechanism is still unclear, the addition of
the CD137 mAb along with neutralization of immunosuppressive
cells and signals shows potential to boost immune function when
added to current cancer therapies (121, 127).
ANTI-GITR MONOCLONAL ANTIBODIES
Glucocorticoid-induced TNF receptor (GITR, TNFRSF18) is
another co-stimulatory member of the TNF receptor superfamily
expressed on T cells, NK cells, and B cells, among other hematopoi-
etic cell types (126). GITR expression is generally low in resting
T and NK cells, is up-regulated after activation, and the receptor
is expressed constitutively at high levels in CD4+Foxp3+ Tregs.
GITR is an activating receptor in T cells, since in vitro or in vivo
engagement with GITR ligand or agonist anti-GITR mAb has
been reported to support the expansion of CD4+ and CD8+ T
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cells and renders T cells resistant to suppression by Tregs (128,
129). Treatment with agonist anti-GITR mAb leads to enhanced
vaccine-induced and endogenous effector T cell responses and
tumor rejection in multiple murine tumor models, and is asso-
ciated with a marked reduction in Treg frequency within the
tumor microenvironment, though the exact mechanism(s) by
which GITR ligation modulates Tregs remains controversial (115,
130–133). Based on these preclinical findings, the first clinical
trial of an agonist anti-human GITR mAb (TRX518) in patients
with advanced melanoma or other solid tumors is now underway
(NCT01239134).
Similar to CD137, there is conflicting evidence about whether
GITR is activating or inhibitory in human NK cells, which may also
reflect differential NK cell responses to GITR engagement between
mice and men (120). While agonist anti-GITR mAb can augment
murine NK cell proliferation and cytotoxicity, GITR engagement
on human NK cells has been reported to block NF-κB activation,
cause release of anti-inflammatory cytokines, suppress NK cell
proliferation, and increase NK cell apoptosis (134). Furthermore,
Baltz et al. found that soluble GITR ligand (sGITRL) is released by
several hematologic malignancies, detectable in patient sera, and
these patients display reduced NK cell cytotoxicity and IFN-γ pro-
duction (135). In CLL, bidirectional GITR/GITRL signaling can
support tumor cell growth by causing release of survival factors,
such as IL-6, IL-8, and TNF, and interfering with rituximab-
induced ADCC responses (136). However, an antagonistic anti-
GITR mAb can block GITR-GITRL interaction, and restore NK
cell-mediated ADCC responses. Finally, a dual strategy has been
developed by Schmiedel et al. that has potential to enhance exist-
ing therapies for AML and CLL (137). An Fc-optimized GITR-Ig
fusion protein was found to block the GITR/GITRL interaction
and target GITRL-bearing cells for ADCC, thus enhancing NK
cell-mediated cytotoxicity of cancer cells. Hence, like anti-CD137
mAb, anti-GITR mAb, and other GITR-targeting therapies have
the potential to boost the effectiveness of current cancer thera-
pies by virtue of pro-inflammatory and cytotoxic effects involving
NK cells.
PD-1 OR PD-L1 BLOCKING MONOCLONAL ANTIBODIES
Programed death 1 (PD-1; CD279) is a member of the B7 family of
co-signaling receptor that is up-regulated on activated T cells, NK
cells, B cells, dendritic cells, and monocytes (138). The intracellu-
lar domain of PD-1 contains an immunoreceptor tyrosine-based
inhibitory motif (ITIM), which can recruit the protein tyrosine
phosphatases SHP-1 and SHP-2 to mediate inhibitory signaling
(139). The engagement of PD-1 by its ligands, PD-L1 or PD-L2,
blocks the immune response in both T and NK cells by inhibiting
PI3K/Akt and Ras activation signaling (140–142). PD-1 expres-
sion also marks “exhaustion” in T cells, and engagement of PD-1
can cause apoptosis of CD8+ T cells and the differentiation of
CD4+ T cells into immunosuppressive Tregs (143–146). In NK
cells, PD-1 engagement impairs activation, conjugate formation,
cytotoxicity, and cytokine production (145, 147, 148). In healthy
tissue, PD-L1-induced inhibitory signaling minimizes damage to
bystander cells and prevents excessive immune responses during
acute infections (149). However, many tumor and viral mod-
els express PD-1 ligands as an immune evasion mechanism. In
contrast, PD-L1 is expressed at low levels on healthy tissue, and
resting NK cells express low levels of PD-1 (144, 145, 147, 148).
IFN-γ can potently up-regulate PD-L1 expression (150), suggest-
ing that localized cytokine production by NK cells and Th1 cells
may actually promote PD-1-based immune evasion by tumors.
The disruption of PD-1/PD-1 ligand interactions can signifi-
cantly potentiate immune responses to viral infections and can-
cer, and antibody-mediated blockade of these interactions has
emerged as a prime target for immune therapies. In the case of
viral persistence in the liver, the abrogation of PD-L1 by siRNA
was shown to enhance the number of intrahepatic NK cells and
CTL, thereby increasing cytotoxicity, cytokine production, viral
clearance, and memory (148). During HIV infection, PD-1 levels
increase on patient NK cells, and this has been shown to diminish
NK cell proliferation (145). PD-L1 expression on tumors and PD-1
expression on tumor-infiltrating lymphocytes have been associ-
ated with poor outcome in renal cell carcinoma patients (151,
152). We have recently reported significantly increased expression
of PD-1 on cytolytic NK cells in renal cell carcinoma patients, sug-
gesting that these tumors can directly suppress tumor-infiltrating
NK cells by this mechanism (153). Remarkably, the PD-1 expres-
sion on NK cells and other leukocytes was rapidly reduced after
surgical resection of the primary renal tumor. Anti-PD-1 or anti-
PD-L1 mAbs block the interaction of PD-1 on T and NK cells
with its ligand, PD-L1 and this restores the function of exhausted
cytolytic T cells, augments T cell proliferation, and enhances NK
cell cytokine production and cytotoxicity responses, leading to
enhanced anti-tumor effector responses and tumor regression in
multiple murine models (146, 149). In clinical trials of anti-PD-1
and anti-PD-L1 antibodies to treat a variety of solid tumors, objec-
tive, often durable responses were seen in up to a third of patients,
demonstrating proof of principle for this approach, and patients
that responded to the treatment were shown to express PD-L1 in
their tumors (154, 155). Further clinical trials of several candidate
antibodies in both solid and hematologic cancers are ongoing.
In studies of MM patients, Benson et al. found upregula-
tion of PD-1 on NK cells in conjunction with PD-L1 expres-
sion on MM cells, and in vitro treatment with an anti-PD-
1 mAb enhanced NK cell conjugation with PD-L1-expressing
MM target cells, resulting in enhanced cytotoxicity and IFN-
γ production (147). In the same study, in vitro treatment with
lenalidomide was shown to further enhance NK cell responsive-
ness by lowering PD-L1 expression on MM cells. In a mouse
model of MM, Hallett et al. also saw increased levels of PD-
L1 on MM cells, along with an exhausted phenotype in T cells,
release of immunosuppressive IL-10 and expansion of Treg cells
accompanied by increased levels of PD-1 on T and NK cells
(144). Blockade of the PD-1/PD-L1 interaction with a PD-L1-
specific mAb increased mouse survival by 40%. Like CS1, PD-1
expression persists after stem cell transplant and prior treat-
ment, so PD-1 is a reliable target in relapsed or refractory can-
cer. Although PD-1 upregulation on human NK cells has only
been reported in MM and renal cell carcinoma to date, its
expression may be elevated in a variety of cancers as a mech-
anism to suppress anti-tumor responses. Therefore, the addi-
tion of PD-1/PD-L1 blocking mAb to an existing treatment
regimen shows encouraging promise in boosting anti-tumor and
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Table 1 | Summary of some major therapeutic agents discussed in the text.
Agent Examples NK cell-specific mechanism Disease studied Reference
Immuno-
modulating drugs
(IMiDs)
Thalidomide,
lenalidomide,
pomalidomide
Stimulate NK and T cells to release
cytokines, kill tumor cells, block
angiogenesis
MM, leukemia, NHL,
pancreatic, esophageal,
prostate
Sampaio et al. (33), D’Amato et al. (34),
(35) Hayashi et al. (44), Wu et al. (45),
Quach et al. (36), clinicaltrials.gov
Proteasome
inhibitors
Bortezomib Induce tumor cell death, increase
NKG2D ligand expression
MM, leukemia, lymphoma,
hepatocellular
Armeanu et al. (160), Shi et al. (53), (55)
Moreau (156), clinicaltrials.gov
Anti-CS1 antibody Elotuzumab Triggers NK cell ADCC MM Hsi et al. (65), Tai et al. (66), (54) Benson
and Byrd (67), Moreau (156)
Anti-KIR2DL
antibody
IPH2101, IPH2102
(Lirilumab)
Blocks inhibitory KIR MM, leukemia Binyamin et al. (80), Sola et al. (81),
Benson et al. (51), Vey et al. (83),
clinicaltrials.gov
HDAC inhibitors Valproic acid,
panobinostat,
vorinostat
Increase NKG2D ligand expression MM, leukemia, Hodgkin’s
lymphoma, hepatocellular
Armeanu et al. (93), Yamanegi et al.
(104), Moreau (156), Yang et al. (105),
clinicaltrials.gov
Anti-CD137
antibodies
BMS-663513
(urelumab)
Augment NK cell ADCC,
co-stimulatory in T cells
NHL, melanoma, breast
cancer
Baessler et al. (119), Buechele et al.
(121), Kohrt et al. (125), clinicaltrials.gov
Anti-GITR
antibodies
TRX518 Block GITR/GITRL in NK cells,
co-stimulatory in T cells, neutralize
Tregs
Solid tumors, melanoma clinicaltrials.gov
Anti-PD-1
antibodies
BMS-936558
(nivolumab), CT-011,
MK-3475
Block PD-1 receptor, block
PD-1/PD-L1 interaction in NK and T
cells
Hepatitis C, renal, prostate,
melanoma, MM, colorectal,
NHL, NSCLC
Benson et al. (147), Brahmer et al. (154),
Rosenblatt et al. (161), Gardiner et al.
(162), Lipson et al. (163), clinicaltrials.gov
Anti-PD-L1
antibodies
BMS-936559,
MSB0010718C,
MPDL3280A
Block PD-L1 interaction with
receptor PD-1 in NK and T cells
Solid tumors, melanoma,
leukemia, MM, breast, NHL
Sznol and Chen (149), clinicaltrials.gov
HDAC, histone deacetylase; ADCC, antibody-dependent cellular cytotoxicity; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung
cancer.
anti-viral responses by several immune cell types, including NK
cells, through counteracting a potent mechanism of immune
evasion.
CONCLUSION
A variety of new therapeutic agents have recently become avail-
able to potentiate NK cell responses in cancer patients, and many
of these drugs are either approved or undergoing clinical trials
(see Table 1). Here we have discussed a representation of this
expanding toolbox of agents that allows clinicians to potentiate
NK cell functions and thereby enhance anti-tumor therapy. Major
future goals will be to expand upon these therapeutic options, bet-
ter define mechanisms of action for these agents, identify specific
combination therapies that are most effective at boosting NK (and
T) cell function, and identify biomarkers (e.g., PD-L1 expression
on tumor cells) that may better predict which patients are most
likely to respond to these immune therapies. Furthermore, while
MM has served as an appropriate proving ground for testing the
therapeutic efficacy of several of these agents (156), they will need
to be tested on other cancers, as well as viral infections and other
disease states, to expand their usefulness.
Many of these agents are already being tested in conjunction
with other immune therapies; especially in combination with
ADCC-inducing mAbs that target NK cells to attack tumors.
Certainly any new therapy utilizing immunostimulatory mAbs
must be carefully evaluated in a stepwise manner to avoid pos-
sible adverse side effects, such as autoimmunity (113). However,
combination therapies allow clinicians to take advantage of mech-
anistic synergies that can effectively boost NK cell function using
agents that have limited impacts when used alone. An appropriate
starting platform combines strategies that boost the immune sys-
tem and block immune suppression (157), and the hard wiring
of NK cells makes them particularly receptive to this strategy.
Of particular interest, several phase I clinical trials are currently
in progress that combine antibodies designed to block multiple
inhibitory immune receptors on NK cells and other leukocytes
simultaneously. These include combining the anti-CTLA antibody,
ipilimumab with the anti-KIR antibody, IPH2102 (lirilumab) to
treat advanced tumors (NCT01750580) and an anti-PD-1 anti-
body (nivolumab) in combination with either ipilimumab to treat
melanoma (NCT01024231) or with lirilumab to treat solid tumors
(NCT01714739). Combination therapies may also allow the use
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of more toxic conventional anti-tumor therapies at lower doses
when new therapies are added. Also, patients who have weakened
immune function, due to prior radiotherapy or chemotherapy,
may particularly benefit from NK cell boosting therapies.
In using these immune therapies, it is important to consider
the phenotype of individual patients (158, 159). It is possible that
most of these agents can be used together in various combina-
tions or with conventional therapies, depending on the biomarkers
present in a particular tumor environment. Altogether, there are
several new tools in the medicine cabinet that offer the possibility
to improve patient outcomes through boosting NK cell func-
tions. While no one-size-fits-all solution is available to universally
improving anti-tumor therapy, proper patient screening should
allow the application of personalized combination therapies that
harness the beneficial attributes of NK cell-mediated anti-tumor
responses to systematically improve overall patient survival.
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